Market Research Report - 121231
Osteoporosis Drugs: Technologies and Global Markets
|Published by||BCC Research|
|Published||Content info||198 Pages|
This study intends to provide readers with an understanding of the global market for prescription drugs that treat and prevent osteoporosis. The study describes the industry structure and major participants in the osteoporosis drugs market, market dynamics and competitive aspects, current developments and future market trends, to assist in understanding the market and identifying areas of commercial interest and potential in osteoporosis.
The study provides an assessment of the current market status, along with an analysis of the patient population, marketed drugs, market revenues, and company shares. The unmet needs of the osteoporosis market, and the challenges that companies must overcome to compete in this market, along with the future trends that shape the industry are also discussed. Future market revenues are forecast for the global market, major drug classes, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of osteoporosis.
Osteoporosis is a skeletal disorder experiencing increasing prevalence globally, due mainly to the aging of the population and the increasing life expectancy worldwide. Osteoporosis fractures are a major cause of disability and morbidity, particularly among older people, and lead to decreased quality of life and increased costs due to disability and need for assisted living. The market for osteoporosis drugs is large, with global revenues exceeding $8.4 billion in 2008, and projected to grow. Prescription drugs for this indication could have great commercial success; four currently marketed drugs in this indication had global revenues of more than $1 billion at some point in their lifecycle. Additionally, several new drugs are projected to enter the market through 2014 and are expected to contribute to the overall osteoporosis market growth.
The report intends to provide a current market snapshot and future developments in the osteoporosis drugs market covering the period from 2007 through 2014. The report describes the existing drug classes approved for these indications, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormones (PTHs), calcitonins, dual-action bone agents (DABAs), and hormone replacement therapies (HRTs). The pipeline of drugs in clinical trials for these indications is also presented and analyzed.
The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, Securities and Exchange Commission (SEC) filings, trade organizations and publications, online databases, and medical and scientific literature.
The base year for analysis and forecast is 2008. Revenue forecasts are provided for the period of 2009 to 2014. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient population; unmet market needs; existing products patent expiration dates; the threat of generic substitution; new market entrants; and their value proposition and differentiation.
This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes. >